318 related articles for article (PubMed ID: 33322163)
21. Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma.
McKay RR; Bossé D; Choueiri TK
J Clin Oncol; 2018 Oct; ():JCO2018790253. PubMed ID: 30372392
[TBL] [Abstract][Full Text] [Related]
22. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
24. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
25. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
26. The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
[TBL] [Abstract][Full Text] [Related]
27. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
Tannir NM; Pal SK; Atkins MB
Oncologist; 2018 May; 23(5):540-555. PubMed ID: 29487224
[TBL] [Abstract][Full Text] [Related]
28. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
29. First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.
Loo V; Salgia M; Bergerot P; Philip EJ; Pal SK
Target Oncol; 2019 Dec; 14(6):639-645. PubMed ID: 31595385
[TBL] [Abstract][Full Text] [Related]
30. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
31. Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.
Cetin B; Kosar A
Int Urol Nephrol; 2019 Dec; 51(12):2107-2117. PubMed ID: 31468288
[TBL] [Abstract][Full Text] [Related]
32. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
Atkins MB; Tannir NM
Cancer Treat Rev; 2018 Nov; 70():127-137. PubMed ID: 30173085
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade.
Larroquette M; Lefort F; Heraudet L; Bernhard JC; Ravaud A; Domblides C; Gross-Goupil M
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551715
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
[TBL] [Abstract][Full Text] [Related]
35. IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma.
Rizzo M; Varnier L; Pezzicoli G; Pirovano M; Cosmai L; Porta C
Front Oncol; 2022; 12():990568. PubMed ID: 36059687
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
37. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy.
Buti S; Leonetti A; Dallatomasina A; Bersanelli M
Core Evid; 2016; 11():23-36. PubMed ID: 27621699
[TBL] [Abstract][Full Text] [Related]
38. Response of Primary Renal Cell Carcinoma to Systemic Therapy.
Bossé D; Lin X; Simantov R; Lalani AA; Derweesh I; Chang SL; Choueiri TK; McKay RR
Eur Urol; 2019 Dec; 76(6):852-860. PubMed ID: 31594707
[TBL] [Abstract][Full Text] [Related]
39. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
Doycheva I; Thuluvath PJ
J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
Osanto S; van der Hulle T
Ther Adv Urol; 2018 Mar; 10(3):109-123. PubMed ID: 29662541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
